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Abstract The impact of phage predation on bacterial pathogens in the context of human  
disease is not currently appreciated. Here, we show that predatory interactions of a phage with an 
important environmentally transmitted pathogen, Vibrio cholerae, can modulate the evolutionary 
trajectory of this pathogen during the natural course of infection within individual patients. We 
analyzed geographically and temporally disparate cholera patient stool samples from Haiti and 
Bangladesh and found that phage predation can drive the genomic diversity of intra-patient  
V. cholerae populations. Intra-patient phage-sensitive and phage-resistant isolates were isogenic 
except for mutations conferring phage resistance, and moreover, phage-resistant V. cholerae 
populations were composed of a heterogeneous mix of many unique mutants. We also observed 
that phage predation can significantly alter the virulence potential of V. cholerae shed from cholera 
patients. We provide the first molecular evidence for predatory phage shaping microbial community 
structure during the natural course of infection in humans.
DOI: 10.7554/eLife.03497.001
Main Text
Traditional views of host–pathogen interactions are of a battle between two opposing organisms. This 
perspective is being challenged with greater appreciation of the influence of the host's microbial eco-
system on these interactions (Lozupone et al., 2012). Bacteriophages influence bacterial populations 
in many ecosystems and specifically temperate phages play a role in many diseases through lysogenic 
conversion (Brüssow et al., 2004). In contrast, the impact of lytic phage predation on bacterial patho-
gens in the context of human disease is under-appreciated. Vibrio cholerae is a water-borne pathogen 
responsible for the diarrheal disease cholera. In order for V. cholerae to colonize the human small 
intestine and elicit diarrhea, it produces a set of virulence determinants including cholera toxin 
(Herrington et al., 1988). The ToxR signaling cascade activates expression of these virulence fac-
tors in response to host environmental stimuli (Miller et al., 1987; Taylor et al., 1987; DiRita et al., 
1991; Childers and Klose, 2007). Cholera epidemics appear with regular seasonality in regions like 
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Bangladesh (Faruque et al., 2005) and can arise unpredictably in vulnerable regions as exemplified 
by the epidemic that recently began in Haiti following the single-source introduction of a pandemic 
V. cholerae O1 strain from another continent (Chin et al., 2011; Cravioto et al., 2011; Frerichs et al., 
2012; Katz et al., 2013). Lytic phages are hypothesized to impact cholera disease burden in Bangladesh 
(Faruque et al., 2005). The predation of V. cholerae by phages following their co-ingestion from the 
environment is central to this hypothesis; however, molecular evidence in support of this hypothesis is 
lacking.
We recently described the ICP2 species of V. cholerae-specific, virulent podoviruses that are 
found sporadically in cholera patient stool samples collected since 2001 in Bangladesh (Seed et al., 
2011 and present study). To begin to address the geographic diversity of cholera phages in patient 
stools, we tested by plaque assay for the presence of phages within nine Haitian cholera patient stool 
samples collected in 2013. We identified one sample that had a high titer of phage (108 PFU/ml) rela-
tive to V. cholerae (105 CFU/ml). Whole genome sequencing and comparative analysis of this phage, 
named ICP2_2013_A_Haiti, revealed 84% identity over 93% of its genome to ICP2_2011_A, a phage 
isolated from Bangladesh in 2011. An alignment of the annotated ICP2 genome (Seed et al., 2011) 
with the three available ICP2-related isolates shows that synteny is conserved between these geo-
graphically distinct phages, with no significant genome rearrangements observed (Figure 1—figure 
supplement 1). The Haitian ICP2 isolate is strikingly similar, although clearly distinct, from Bangladeshi 
ICP2 isolates, and is the first lytic phage reported to be associated with epidemic V. cholerae in Haiti.
Remarkably, we observed that most V. cholerae isolates recovered from the same stool sample as 
ICP2_2013_A_Haiti were resistant to infection by this phage. We investigated phenotypic heteroge-
neity within this stool sample by testing 269 single colony isolates for sensitivity to ICP2_2013_A_Haiti 
and found that 267 (>99%) were phage-resistant. Eight phage-resistant isolates and the two phage-
sensitive isolates from this sample were subjected to whole genome sequencing. All 10 isolates were 
eLife digest Cholera epidemics occur seasonally in areas such as Bangladesh, and outbreaks 
can also strike in vulnerable regions, as has occurred recently in Haiti. The disease is caused by 
Vibrio cholerae, a water-borne bacterium that colonizes the small intestine, and its symptoms 
include severe diarrhea and vomiting which can lead to death if the patient is not treated promptly.
Lytic phages are viruses that specifically attack and kill bacteria. After replicating many times 
inside the bacterial cell, the phages break open and destroy the cell. Over time a bacterial 
population can evolve to resist this phage ‘predation’; however, it is not known if bacterial 
pathogens need to defend themselves against phage attack when they infect humans. It had been 
suggested that phages might affect the progress of cholera infections in people, but molecular 
evidence that supports this hypothesis was lacking.
When testing stool samples from Haitian cholera patients, Seed et al. found one sample 
contained a lot of lytic phage relative to the amount of V. cholerae present. This phage was very 
similar to—but distinct from—a phage found in Bangladeshi patients.
The V. cholerae bacteria isolated from the stool sample were resistant to attack by the phage. 
Sequencing the genome of individual bacteria from this sample revealed that each had a mutation 
that made them resistant to the phage; and while many types of these mutations were found, these 
were the only differences between all the V. cholerae bacteria in this patient sample. This suggests 
that this resistance developed independently many different times within the patient due to strong 
selective pressure from phage predation.
When Seed et al. looked at a phage-positive stool sample from a Bangladeshi patient, more 
mutations that made the bacteria resistant to this phage were found; however, these mutations 
were different again from the ones in the Haitian bacteria. Because of the nature of these mutations 
the bacteria from this patient were rendered unable to cause disease and non-transmissible.
This work shows that phages can indeed have access to pathogenic bacteria during human 
infection. It also indicates that the pressure imposed by phage predation can, in some cases, be  
so strong that the bacteria lose their virulence and ability to spread to other humans in order to 
become resistant to the phage.
DOI: 10.7554/eLife.03497.002Microbiology and infectious disease
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isogenic except for mutations within ompU encoding the major outer membrane porin (Supplementary 
file 1). Furthermore, the ompU mutations in the eight phage-resistant isolates were heterogeneous. 
We sequenced ompU from an additional 11 phage-resistant isolates from this stool sample and found 
a total of six unique ompU alleles (Figure 1A). When each of these alleles was used to replace ompU 
in a clean genetic background, all conferred resistance to ICP2, yet produced normal amounts of 
OmpU (Figure 2 and data not shown), suggesting that ICP2 uses OmpU as a receptor to initiate infec-
tion and that the mutations disrupt this interaction. These data showing that intra-host V. cholerae 
isolates are isogenic, only differing in ICP2 resistance mutations, indicates that they diverged within 
the patient. Furthermore, the presence of multiple different ICP2 resistance mutations within this sin-
gle host suggests that selection of phage resistance occurred multiple, independent times during the 
course of infection. We also found evidence for ICP2-mediated selection of OmpU mutants in isolates 
from Bangladesh. Analysis of the ompU sequence from 54 clinical isolates collected between 2001 and 
Figure 1. The presence of V. cholerae OmpU and ToxR mutants present within and between cholera patients. (A) Graphical depiction and frequency of 
OmpU mutants found within a stool sample containing ICP2_2013_A_Haiti phage (108 PFU/ml) from a single Haitian patient (top) and from different 
patients in Bangladesh (n = 54) (bottom). (B) Predicted membrane topology of mature OmpU generated using Pred-TMBB (Bagos et al., 2004). 
Locations of amino acid substitutions or insertions carried by V. cholerae clinical isolates are indicated. (C) Graphical depiction and frequency of ToxR 
mutants found within a stool sample containing ICP2_2011_A (109 PFU/ml) from a single Bangladeshi patient. Amino acid substitutions or nonsense 
mutations (asterisks) are in orange and duplications are in blue.
DOI: 10.7554/eLife.03497.003
The following figure supplements are available for figure 1:
Figure supplement 1. ICP2_2013_A_Haiti is closely related to ICP2 bacteriophages from Bangladesh. 
DOI: 10.7554/eLife.03497.004
Figure supplement 2. Identification of OmpU mutants in samples collected at the International Centre for Diarrheal Disease Research, Bangladesh 
between 2001–2011. 
DOI: 10.7554/eLife.03497.005Microbiology and infectious disease
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2011 showed that 15% had non-synonomous mutations (Figure 1A, Figure 1—figure supplement 2) 
and these alleles were sufficient for ICP2 resistance (Figure 2). One of the OmpU mutants, G325D, was 
observed in clinical isolates from Haiti and Bangladesh (Figure 1A). Interestingly, seven of the eight 
mutant OmpU proteins detected in the Haitian and Bangladeshi clinical isolates had alterations in two 
predicted extracellular loops, while the eighth had an altered transmembrane segment adjacent to the 
first of these extracellular loops (Figure 1B). This suggests that ICP2 interacts specifically with these 
exposed loops to initiate infection.
We also tested for V. cholerae population heterogeneity within an ICP2-positive stool sample iso-
lated in Bangladesh in 2011. Of 46 single colony isolates tested for sensitivity to ICP2_2011_A, 22% 
were resistant to the phage. Whole genome sequencing of two phage-sensitive and four phage-
resistant isolates from this sample revealed that the strains were isogenic, except that phage-resistant 
isolates had nonsense mutations in toxR, the direct transcriptional activator of ompU (Crawford et al., 
1998; Supplementary file 2). We sequenced toxR from an additional eight phage-resistant isolates 
from this stool sample and found that, analogous to what was observed in the Haitian patient sample, 
there were multiple unique toxR alleles, which included two non-synonomous and two nonsense muta-
tions (Figure 1C). Each of the four mutant toxR alleles conferred ICP2 resistance and abrogated 
expression of OmpU when used to replace wild-type toxR in a clean genetic background (Figure 2). 
Both ICP2-sensitivity and OmpU expression were restored to the clinical toxR mutants by expressing 
ompU in trans or by reverting the toxR allele to wild-type (data not shown), indicating that these 
mutant toxR alleles are necessary and sufficient for ICP2 resistance and that this resistance is mediated 
through loss of OmpU expression.
To address the potential consequences of the phage-resistance mutations on V. cholerae fitness, we 
tested the four most frequently isolated ompU alleles and all four toxR alleles in survival and growth 
assays. Recent Tn-seq analyses of V. cholerae showed that OmpU is critical for fitness in an infant rabbit 
infection model (Fu et al., 2013; Kamp et al., 2013) and for dissemination from the host into pond 
water (Kamp et al., 2013). OmpU has also been shown to be important for protection against the 
bactericidal effect of bile salts (Provenzano et al., 2001), cationic peptides (Mathur and Waldor, 
2004), and intestinal organic acids (Merrell et al., 2001). When we tested for survival in bile and for 
competitive fitness in pond water we found that the four OmpU mutants are fully fit (Figure 3A,B), 
Figure 2. OmpU expression of OmpU and ToxR mutants and their sensitivity to ICP2. Outer membrane 
fractions were prepared from samples matched by equivalent OD600 units. Samples were separated by 
SDS-PAGE and subjected to Western blot analysis using rabbit polyclonal antisera against OmpU. The 
sensitivity of each strain to ICP2_2013_A_Haiti is represented as a histogram of the efficiency of plaquing, 
which is the plaque count ratio of a mutant V. cholerae strain to that of the wild-type strain. The limit of 
detection for plaque assays was 10−7.
DOI: 10.7554/eLife.03497.006Microbiology and infectious disease
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consistent with their wild-type levels of OmpU expression (Figure 2). Moreover, the OmpU(G325D) 
mutant was fully virulent in a single round, competitive infection in infant rabbits (Figure 4, first col-
umn). However, the OmpU mutants, particularly the A195T and G325D mutants, showed a mild com-
petitive defect after multiple passaging in growth medium (Figure 3C). The mild growth defect of the 
OmpU mutants in conjunction with the low prevalence of ICP2 (Seed et al., 2011) may explain why the 
ICP2-resistant ompU variants do not become fixed in the population (Figure 1—figure supplement 2). 
In sharp contrast, in the presence of ICP2 we observed a 10,000-fold enrichment of the OmpU(G325D) 
Figure 3. The fitness cost of clinically relevant OmpU and ToxR mutations. (A) Clinically relevant OmpU mutants retain fitness in the presence of bile.  
*p < 0.05 significantly different means for the compared data sets (Mann–Whitney U Test). (B) OmpU mutants retain competitive fitness in pond water.  
*p < 0.05 significantly different from wild-type control (Kruskal–Wallis and post hoc Dunn's multiple comparison tests). (C) OmpU mutants have slight 
competitive fitness defects when serially passaged in Luria–Bertani broth (for ca. 58 generations). *p < 0.05 or ****p < 0.0001 significantly different from 
wild-type control (Kruskal–Wallis and post hoc Dunn's multiple comparison tests). (D) ToxR mutants are attenuated in vivo using the infant mouse 
colonization model. **p < 0.01 or ***p < 0.001 significantly different from the in vitro median (Mann–Whitney U Tests). The horizontal bars indicate the 
median of each data set. Open symbols represent data below the limit of detection.
DOI: 10.7554/eLife.03497.007
The following figure supplement is available for figure 3:
Figure supplement 1. Clinical isolates harboring ToxR mutations are severely attenuated for infection. 
DOI: 10.7554/eLife.03497.008Microbiology and infectious disease
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mutant over the wild-type after infection of infant 
rabbits (Figure 4), indicating that strong selective 
pressure is imposed by phage predation during 
V. cholerae infection. This emulates what we   
hypothesize happens in human infections in the 
presence of ICP2 and is the first demonstration of 
phage predation of V. cholerae in the context of a 
diarrheal disease model.
V. cholerae strains harboring any of the four 
ToxR mutations were avirulent in the infant mouse 
model of infection and were indistinguishable 
from a ΔtoxR mutant (Figure 3D). The clinical 
isolates containing these mutations were also at 
least 100-fold attenuated (Figure 3D—figure 
supplement 1), indicating that these isolates do 
not harbor compensatory mutations. The cyto-
plasmic amino terminus (D17-E112) of ToxR where 
the two non-synonomous mutations mapped 
has homology to the winged helix-turn-helix 
family of transcription activators and is involved 
in DNA binding and transcriptional activation 
(Miller et al., 1987; Ottemann et al., 1992).   
A number of point mutations in this domain 
were previously shown to abrogate activation of 
ompU and virulence genes (Ottemann et al., 
1992; Morgan et al., 2011). The severe viru-
lence defects of the two non-synonomous toxR 
mutants from the Bangladeshi patient sample 
(Figure 3D) are consistent with an inability of 
the encoded mutant ToxR proteins to activate these genes. These toxR mutants would not colo-
nize the human small intestine and be recovered in the secretory diarrhea if ingested (Herrington 
et al., 1988), which further supports our conclusion that these mutants arose due to ICP2 preda-
tion during cholera infection in this individual. This also indicates that, in this patient, predation 
and selection of phage-resistant mutants likely occurred late in infection when colonization and 
virulence gene expression were no longer required for the development of acute symptoms 
(Merrell et al., 2002).
We have shown that lytic phages are an unexpected ‘third party’ that impose significant bacteri-
cidal pressure on an environmentally transmitted pathogen during the natural course of infection   
in humans. We observed that adaptations to phage predation involve tradeoffs in evolutionary fit-
ness and provide a molecular mechanism for phage predation impacting V. cholerae transmission 
and seeding of environmental reservoirs. Our results highlight that host–pathogen interactions are 
embedded within and strongly affected by a complex microbial ecosystem. Predator-prey dynamics 
are notably absent between microbiotal phage and their bacterial hosts in the intestinal ecosystem 
in healthy humans (Reyes et al., 2010). In contrast, our findings indicate that diseased states, 
which are often accompanied by significant bacterial proliferation, likely facilitate these predatory 
interactions.
Materials and methods
Growth conditions, strains and genomic analysis
Strains utilized in this study are listed in Supplementary file 3. Stool specimens and V. cholerae iso-
lates from the International Centre for Diarrheal Disease Research, Bangladesh were collected and 
stored from previous studies (Nelson et al., 2008; Seed et al., 2011, 2012, 2013). Phage (ICP2_2011_A 
and ICP2_2013_A_Haiti) were isolated from cholera rice-water stool samples as described (Seed et al., 
2011). V. cholerae isolates were isolated from stool samples on Luria–Bertani agar with sulfamethoxa-
zole (24 µg/ml), trimethoprim (32 μg/ml), nalidixic acid (20 µg/ml) and streptomycin (Sm) (100 µg/ml). 
Figure 4. Phage predation leads to enrichment of 
OmpU mutant over wild-type in vivo. Competitive 
indices (CI) were determined between wild-type ΔlacZ 
and OmpU G325D in the absence or presence of 
ICP2_2013_A_Haiti at the multiplicity of infection (MOI) 
indicated in infant rabbits 12 hr post-infection. Each 
symbol represents the CI for an individual rabbit and 
the horizontal lines indicate the median for each 
condition. The open symbols represent data below the 
limit of detection for the wild-type strain. **p < 0.01, 
significantly different from no phage control (Kruskal–
Wallis and post hoc Dunn's multiple comparison tests).
DOI: 10.7554/eLife.03497.009Microbiology and infectious disease
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Mutations were introduced using pCVD442-lac as previously described (Seed et al., 2012). Strains 
containing the pMMB67EH vector were grown in the presence of 50 μg/ml ampicillin and 1 mM iso-
propyl-ß-D-thiogalactopyranoside (IPTG).
V. cholerae and phage genomic libraries were generated (Lazinski and Camilli, 2013) and 
sequenced using an Illumina HiSeq2000 (Tufts University Core Facility). Sequence reads from   
each V. cholerae isolate were mapped to the reference genome V. cholerae O1 2010EL-1786 (for 
Haitian isolates, accession numbers NC_016445.1 and NC_016446.1) or to V. cholerae O1 N16961 
(for Bangladeshi isolates, accession numbers NC_002505.1 and NC_002506.1) and mutations 
were identified using Varscan v2.3.6 (Koboldt et al., 2012) and CLC Genomic Workbench soft-
ware (Version 6.8; CLC Bio, Denmark). Variants were called as being present (different allele than 
reference), absent (the same allele as reference) or low-coverage (<15×; in which case no call   
was made).
Preparation of outer membrane fractions and Western blotting
Cultures were grown to mid-exponential growth phase in Luria–Bertani (LB) broth at 37°C with aera-
tion. Bacteria were re-suspended in 200 mM Tris–HCl, pH 8.0 and 2 mM EDTA. Sucrose was added to 
a final concentration of 20% followed by lysozyme treatment for 10 min at 37°C. Using a dry ice/
ethanol bath, samples were freeze-thawed twice followed by DNAse I treament for 20 min at room 
temperature. Samples were spun for 5 min at 16,100×g to pellet the membrane fraction. The pellets 
were re-suspended in 1% Triton X-100, 10 mM MgCl2, and 50 mM Tris–HCl, pH 8.0 and incubated at 
37°C for 20 min. Samples were spun again for 5 min at 16,100×g to separate the inner membrane from 
the outer membrane. The pellets, which contain the outer membrane proteins, were re-suspended in 
200 mM Tris–HCl, pH 8.0.
Outer membrane fractions were boiled for 10 min in sample buffer containing sodium dodecyl 
sulfate and β-mercaptoethanol and separated on a NuPAGE 4–12% Bis-Tris polyacrylamide gel (Life 
Technologies, Carlsbad, CA). Protein gels were transferred to a nitrocellulose membrane for Western 
blotting. Membranes were probed with rabbit polyclonal antisera against V. cholerae OmpU (gift of 
James Kaper). A Cy5 goat anti-rabbit antibody was used to develop the blot.
Evaluation of in vitro fitness
Strains (grown to OD600 = 0.5) were assessed for their ability to survive 0.2% porcine bile (Sigma, 
St. Louis, MO) in 0.85% NaCl for 1 hr at room temperature. Pond water survival assays were done as 
described previously (Kamp et al., 2013) at 30°C for 48 hr. Competition experiments were performed 
between the strain of interest (lacZ+) and the appropriate control strain (ΔlacZ), and outputs were 
plated on LB agar plates containing 100 µg/ml Sm and 40 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal).
Animals
All animal experiments were in accordance with the rules of the Department of Laboratory Animal 
Medicine at Tufts Medical Center. Infant mouse colonization assays and in vitro controls were done as 
described previously (Seed et al., 2012). 3-day old infant rabbits were pre-treated with Cimetidine-
HCL (Morton Grove Pharmaceuticals, Morton Grove, IL) 3 hr prior to infection (Kamp et al., 2013) 
and infected with ∼5 × 108 CFU in 2.5% sodium bicarbonate buffer (pH 9). A 1:1 mixture of wild-type 
to mutant (for experiments without phage) or 10:1 wild-type to mutant (for experiments including 
phage) was used. For experiments involving the addition of phage, phage were added immediately 
before intragastric inoculation to each rabbit inoculum to limit phage adsorption ex vivo (phage 
were in contact with the bacterial inoculum for ∼30–60 s prior to gavage of each animal). Rabbits were 
euthanized ∼12 hr post-inoculation and cecal and/or small intestinal fluid was collected by puncture. 
As with the in vitro assays, the competing strains were enumerated on LB agar plates containing 
100 µg/ml Sm and 40 µg/ml X-gal.
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